Ascentage Pharma Group International (6855) AI Stock Analysis

• Market Cap: HK$24.44B
• Dividend Yield: N/A
• Average Volume (3M): 2.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: -56.94%
• EPS Growth: -190.36%
• Country: HK
• Employees: 567
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.89
• Shares Outstanding: 373,319,730
• 10 Day Avg. Volume: 1,948,642
• 30 Day Avg. Volume: 2,293,783
• PEG Ratio: 0.54
• Price to Book (P/B): 48.81
• Price to Sales (P/S): 13.15
• P/FCF Ratio: -95.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$102.35
• Price Target Upside: 64.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$63.00 ▲(1.12% Upside)

The overall stock score of 45 reflects significant challenges in financial performance, particularly in profitability and cash flow generation, despite strong revenue growth. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and showing oversold signals. Valuation metrics are weak due to negative earnings and lack of dividends, highlighting the need for financial improvements to enhance investor appeal.

Ascentage Pharma Group International Business Overview & Revenue Model

Company Description

Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.

How the Company Makes Money

Ascentage Pharma generates revenue through multiple streams, primarily from the development and commercialization of its pharmaceutical products. The company earns money by advancing its drug candidates through clinical trials, ultimately seeking regulatory approval for commercialization. Additionally, Ascentage engages in strategic partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving specific development targets, and royalties on future sales. These partnerships are crucial for funding research and development activities, as well as expanding its market reach. The company may also explore licensing agreements for its drug candidates, adding to its revenue potential.

Ascentage Pharma Group International Financial Statement Overview

Summary

Ascentage Pharma Group International shows strong revenue growth, yet struggles with profitability and cash flow generation. The increasing revenue is overshadowed by negative margins and high leverage, posing risks to financial stability. The balance sheet reflects significant debt levels, which require careful management. Overall, the company needs to focus on improving profitability and cash flow to enhance financial health and long-term viability.

Income Statement

The company has demonstrated significant revenue growth, with total revenue increasing from HK$221.98M in 2023 to HK$980.65M in 2024, marking a growth rate of 342%. However, profitability remains a concern as indicated by negative EBIT and net profit margins. The EBIT margin improved from -401.69% in 2023 to -38.63% in 2024, but is still negative, reflecting ongoing challenges in achieving operational efficiency. Gross profit margin is relatively high at 97.03% in 2024, but net profit margin remains deeply negative at -41.33%, indicating persistent net losses.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 6.31 in 2024, highlighting significant leverage and potential financial risk. Stockholders' equity has decreased, raising concerns about financial stability. However, the equity ratio improved slightly to 10.09% in 2024. While total assets increased, the high level of liabilities remains a concern for long-term solvency. Return on equity is negative due to ongoing net losses, emphasizing the need for profitability improvements.

Cash Flow

Cash flow analysis reveals challenges in generating positive operating cash flow, with a substantial reduction from HK$-726.08M in 2023 to HK$0 in 2024. Free cash flow remains negative, reflecting continuous cash outflows that may constrain future growth opportunities. The lack of available data for cash flow ratios further complicates the evaluation of cash flow health. The company needs to address cash flow generation to ensure sustainable operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	390.60M	980.65M	221.98M	209.71M	27.91M	12.45M
Gross Profit	354.93M	951.57M	191.44M	187.71M	24.58M	10.48M
EBITDA	-1.04B	-299.63M	-743.61M	-835.99M	-915.99M	-641.77M
Net Income	-1.16B	-405.43M	-925.64M	-882.92M	-782.42M	-677.61M
Balance Sheet
Total Assets	3.05B	2.62B	2.50B	2.83B	2.94B	1.73B
Cash, Cash Equivalents and Short-Term Investments	1.66B	1.26B	1.10B	1.50B	1.75B	1.03B
Total Debt	1.72B	1.67B	1.80B	1.79B	1.08B	529.70M
Total Liabilities	2.37B	2.34B	2.43B	2.42B	1.71B	884.42M
Stockholders Equity	666.00M	264.19M	60.42M	408.66M	1.23B	846.62M
Cash Flow
Free Cash Flow	-216.89M	-135.65M	-782.92M	-857.20M	-1.04B	-859.88M
Operating Cash Flow	-189.09M	-111.36M	-726.08M	-653.91M	-604.68M	-609.96M
Investing Cash Flow	-935.28M	-362.04M	21.92M	-384.61M	-466.52M	-107.37M
Financing Cash Flow	868.61M	314.77M	368.75M	619.27M	1.78B	1.04B

Ascentage Pharma Group International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 62.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6855, the sentiment is Negative. The current price of 62.3 is below the 20-day moving average (MA) of 67.61, below the 50-day MA of 73.65, and above the 200-day MA of 59.57, indicating a neutral trend. The MACD of -2.71 indicates Positive momentum. The RSI at 33.87 is Neutral, neither overbought nor oversold. The STOCH value of 23.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6855.

Ascentage Pharma Group International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	61 Neutral	HK$34.13B	38.35	27.37%	―	2.57%	18.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6855	45 Neutral	HK$24.44B	-16.84	-161.12%	―	-56.94%	-190.36%
1877	43 Neutral	HK$37.98B	-23.90	-15.06%	―	39.02%	48.26%
1952	41 Neutral	HK$15.99B	-20.63	-15.75%	―	102.73%	38.42%
9969	40 Underperform	HK$21.45B	-111.85	-3.06%	―	68.75%	55.64%

Ascentage Pharma Group International Corporate Events

Ascentage Pharma’s Promising HR-MDS Study: A Potential Game Changer

Study Overview: The clinical study titled ‘A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)’ aims to evaluate the overall survival of patients using Lisaftoclax combined with azacitidine versus a placebo with azacitidine. This study is significant as it targets higher-risk myelodysplastic syndrome, a condition with limited treatment options.

Ascentage Pharma’s Promising Study on Lisaftoclax for AML: A Potential Game-Changer?

Ascentage Pharma Group International is conducting a Phase Ib study titled ‘A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML.’ The study aims to evaluate the safety and pharmacokinetic profile of Lisaftoclax, both as a standalone treatment and in combination with other therapies, for patients with relapsed or refractory acute myeloid leukemia (AML) and related myeloid malignancies. This research is significant as it explores potential new treatment avenues for challenging AML cases.

Ascentage Pharma’s GLORA Study: A Promising Development in CLL/SLL Treatment

Study Overview: The GLORA Study, officially titled ‘A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,’ aims to assess the efficacy and safety of lisaftoclax combined with BTK inhibitors in patients with CLL/SLL who have previously been treated with BTK inhibitors. This study is significant as it explores a potential new treatment option for this patient population.

Ascentage Pharma’s APG-5918: A Promising Anemia Treatment in Phase 1 Trials

Study Overview: Ascentage Pharma Group Inc. is conducting a Phase 1 clinical study titled A Phase 1 Study to Evaluate Safety and Tolerability, Pharmacokinetics and Preliminary of APG-5918 in Healthy Subjects or Anemic Patients. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-5918, a potential treatment for anemia, highlighting its significance in addressing this common condition.

Ascentage Pharma’s Innovative AML Treatment Study: A Market Game Changer?

Study Overview: Ascentage Pharma Group is conducting a pivotal study titled A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (GLORA-3). The study aims to evaluate the efficacy of the combination of APG-2575 (Lisaftoclax) and azacitidine compared to a placebo with azacitidine in patients with acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.

Ascentage Pharma’s APG-2449: A Promising Phase I Study for Advanced Solid Tumors

Study Overview: Ascentage Pharma Group International is conducting a Phase I clinical study titled ‘A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety and effectiveness of APG-2449, a novel tyrosine kinase inhibitor, in treating advanced solid tumors, including lung, esophageal, ovarian cancers, and more. This research is significant as it explores a potential new treatment option for these challenging conditions.

Ascentage Pharma’s Phase 3 Study on Olverembatinib: A Potential Game-Changer for CML Treatment

Study Overview: Ascentage Pharma Group Inc. is conducting a global, multi-center, open-label, randomized, and registrational Phase 3 study titled ‘Study of Olverembatinib (HQP1351) in Patients With CP-CML.’ The study aims to evaluate the efficacy and safety of Olverembatinib in patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP), a condition that requires effective treatment options.

Ascentage Pharma’s APG-2575 Study: A Potential Game-Changer for CLL/SLL Treatment?

Ascentage Pharma Group International is conducting a Phase Ib/II study titled ‘A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL.’ The study aims to evaluate the safety and effectiveness of APG-2575, both as a standalone treatment and in combination with other drugs, for patients suffering from relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

Ascentage Pharma’s Promising Study on Lisaftoclax for CLL/SLL: A Potential Game-Changer?

Study Overview: Ascentage Pharma Group International is conducting a Phase Ib study titled APG-2575CU101, A Phase Ib Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). The study aims to assess the safety and tolerability of lisaftoclax, identify dose-limiting toxicities, and determine the maximum tolerated dose or recommended phase 2 dose. This research is significant as it targets CLL/SLL, conditions with limited treatment options.

Ascentage Pharma’s HQP1351 Study: A Promising Step in Cancer Treatment

Study Overview: Ascentage Pharma Group International is conducting a Phase I study titled ‘A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.’ The study aims to determine the recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HQP1351 in patients with Gastrointestinal Stromal Tumor (GIST) or other solid tumors. This study is significant as it explores a new treatment option for these conditions.

Ascentage Pharma’s Promising Phase I Trial in Pediatric Oncology

Ascentage Pharma Group International is conducting a Phase I clinical trial titled ‘A Phase I Clinical Study of APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors.’ The study aims to evaluate the safety, pharmacokinetic profile, and initial efficacy of the drugs APG-115 and APG-2575 in treating pediatric patients with these conditions. This research is significant as it targets a challenging area in pediatric oncology, potentially offering new therapeutic options.

Ascentage Pharma’s Promising Phase I Study on APG-2449: A Potential Game-Changer in Cancer Treatment

Ascentage Pharma Group International is conducting a Phase I clinical study titled A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors. The study aims to evaluate the safety and efficacy of APG-2449, a promising treatment for challenging cancer types, highlighting its potential significance in oncology.

Ascentage Pharma’s Promising Clinical Study on Advanced Tumors: A Market Perspective

Study Overview: Ascentage Pharma Group is conducting a Phase Ib/II clinical study titled ‘A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors.’ The study aims to evaluate the safety and efficacy of APG-115 combined with a PD-1 inhibitor, toripalimab, in treating advanced liposarcoma and other solid tumors. This research is significant as it explores potential new treatment options for these challenging cancer types.

Ascentage Pharma’s Phase III Study on Olverembatinib: A Potential Game-Changer for GIST Treatment

Study Overview: The study titled A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3) aims to evaluate the efficacy and safety of olverembatinib in patients with SDH-deficient GIST who have undergone prior treatment. This study is significant as it seeks to improve progression-free survival and clinical benefit rates for this patient group.

Ascentage Pharma’s APG-2575: A Promising Study for Lupus Treatment

Study Overview: Ascentage Pharma Group International is conducting a clinical study titled A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus. The study aims to assess the safety and efficacy of APG-2575, a promising treatment for systemic lupus erythematosus (SLE), a chronic autoimmune disease. This study holds significant potential for improving patient outcomes in SLE management.

Ascentage Pharma’s Phase 3 Study on Olverembatinib: A Potential Game Changer for Ph+ALL

Study Overview: Ascentage Pharma Group International is conducting a pivotal Phase 3 study titled ‘A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)’. The study aims to evaluate the efficacy and safety of Olverembatinib, a promising treatment for Ph+ALL, compared to the established drug Imatinib, both in combination with chemotherapy.

Ascentage Pharma Reports Revenue Decline Amidst Strategic Drug Approvals

Ascentage Pharma Group International reported a significant decrease in revenue for the first half of 2025, primarily due to a drop in intellectual property revenue compared to the previous year. Despite this, product sales of Olverembatinib in China saw a substantial increase, attributed to its inclusion in the National Reimbursement Drug List, enhancing its affordability and accessibility. The company also marked a milestone with the approval of Lisaftoclax in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, highlighting its strategic execution in clinical development. This approval positions Ascentage Pharma as a key player in the Bcl-2 inhibitor market, with implications for increased market presence and stakeholder interest.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

Ascentage Pharma’s Lisaftoclax Phase III Trial for HR-MDS Cleared by FDA and EMA

Ascentage Pharma has received clearance from the FDA and EMA to conduct a global Phase III trial of Lisaftoclax, a Bcl-2 inhibitor, in combination with azacitidine for treating higher-risk myelodysplastic syndrome (HR-MDS). This trial, known as GLORA-4, is significant as it is the only registrational Phase III study of a Bcl-2 inhibitor for HR-MDS globally, potentially addressing a major treatment gap and offering a new therapeutic option for patients with this challenging condition.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

Ascentage Pharma Schedules Board Meeting to Review Interim Results

Ascentage Pharma Group International has announced a board meeting scheduled for August 20, 2025, to consider and potentially approve the unaudited interim results for the first half of the year. This meeting is significant as it may impact the company’s financial outlook and provide insights into its operational performance, potentially influencing stakeholder decisions.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.